Earnings call transcript: Almirall misses Q3 2026 profit view as sales rise

Almirall reported weaker-than-expected third-quarter 2026 earnings, missing Wall Street's profit view and revenue estimates. The Spanish dermatology company disclosed an adjusted earnings per share of $0.08, falling short of the forecasted $0.13 and trailing the $290.5 million in revenue by $4.85 million. Sales still climbed 10.1% year-over-year, driven by strong demand in European dermatology, but the reduced earnings weighed on the stock, which fell 1.61% to $11.02 in premarket trading.

Almirall's EBITDA margin reached around 25%, two years ahead of its 2028 target, and the company's two main biologic products, Ilumetri and Ebglyss, continued to fuel growth. Ilumetri, used for psoriasis, posted its best quarter since launch, while Ebglyss, for atopic dermatitis, saw even faster growth. The company's net sales for the first nine months of 2026 were EUR 889 million, up 8.3% from a year earlier.

Almirall's focus on dermatology distinguishes it from broader pharmaceutical peers, and management expressed confidence in the product momentum and pipeline programs set to shape future growth.